临床试验/NCT04531046

NCT04531046进行中（未招募）2 期

Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation

The Lymphoma Academic Research Organisation16 个研究点分布在 2 个国家目标入组 62 人开始时间: 2021年3月10日最近更新: 2024年10月9日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 62
试验地点: 16
主要终点: Complete Metabolic Response (CMR) - determined by investigator

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.

详细描述

Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy directed against CD19 which has been approved for the treatment of relapse/refractory diffuse large B-cell lymphoma DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or more lines of systemic therapy.

But administrating CAR T-cells earlier in the therapeutic strategy may be beneficial to patients.

Axi-cel will improve the outcome of patients with DLBCL who are refractory or relapse early (i.e. within 1 year from end of treatment) after first-line therapy and who are not eligible for Autologous Stem Cell Transplantation (ASCT).

Transplant-ineligible patients will include those who are deemed ineligible for high-dose chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) due to age, comorbidity, or prior ASCT.

The primary endpoint will be complete metabolic response (CMR) at 3 months after Axi-cel infusion.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patient who understands and speaks one of the country official languages and signed Informed Consent Form
•Histologically proven relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), follicular lymphoma Grade 3B per World Health Organization (WHO) 2016 classification and Primary mediastinal Bcell lymphomas. Indolent B-NHL who transformed into aggressive B-NHL and were previously treated with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP) are eligible.
•Tumoral tissue (at diagnosis or relapse) available for central pathology review, exploratory endpoints and ancillary studies
•Positron-emission tomography (PET)-positive disease
•Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (CHOP) or CHOP-like chemotherapy
•Relapsed or refractory disease after first-line chemoimmunotherapy (full dose of R-CHOP or R-CHOP-like regimen), documented by PET-scan
•At least 2 weeks must have elapsed since any prior systemic cancer therapy at the time the patient provides consent
•Patients must be autologous stem cell transplantation (ASCT)-ineligible
•Patients must be CAR-T-eligible
•Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 12 months are not considered to be of childbearing potential)

排除标准

•Patients who received more than one prior line of systemic therapy
•Patients who are intolerant to first-line therapy or who received suboptimal first-line therapy, including dose-reduced R-CHOP ("R-miniCHOP"), and those who discontinued prematurely first-line therapy due to toxicity are not eligible
•Prior CD19 targeted therapy
•Patients with cardiac atrial or cardiac ventricular lymphoma involvement
•Requirement for urgent therapy due to tumor mass effects, such as bowel obstruction or blood vessel compression
•Patient with clinically significant pleural effusion
•History of another primary malignancy that has not been in remission for at least 2 years (except for nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast))
•Patients with detectable Central Nervous System (CNS) lymphoma
•History or presence of non-malignant CNS disorder, such as seizure disorder requiring anti-convulsive therapy, cerebellar disease, or any autoimmune disease with CNS involvement disease
•Active hepatitis B or hepatitis C infection, positive serology of human immunodeficiency virus (HIV) and syphilis at the time of screening
•Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or axi-cel administration
•History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease
•History of autoimmune disease requiring systemic immunosuppression and/or systemic disease modifying agents within the last year
•History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computed tomography (CT) scan at screening.
•History of severe immediate hypersensitivity reaction to tocilizumab or any of the agents used in this study
•History of severe immediate hypersensitivity reaction attributed to aminoglycosides, cyclophosphamide and fludarabine
•Treatment with a live, attenuated vaccine within 6 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the course of the study
•Women of childbearing potential who are pregnant or breastfeeding (from the time of consent during treatment and for at least 6 months after conditioning chemotherapy dosing or axicabtagene ciloleucel dosing, whichever is later)
•In the investigator's judgment, the patient is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
•Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

研究组 & 干预措施

axicabtagene ciloleucel

Experimental

Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg

干预措施: axicabtagene ciloleucel (Drug)

结局指标

主要结局

Complete Metabolic Response (CMR) - determined by investigator

时间窗: 3 months from axi-cel infusion

CMR from axi-cel infusion (without additional anticancer therapy) based on investigator disease assessment according to PET-scan (using the Lugano Response Criteria)

次要结局

Event-free survival (EFS) based on investigator disease assessment(at 12 months)
Best objective response(at 3 years)
Number of Serious Adverse Events (SAE)(at 30 days after axi-cel infusion)
Modified EFS (mEFS) based on central imaging review(at 12 months)
Event-free survival (EFS) based on central imaging review(at 12 months)
Complete Metabolic Response (CMR) - determined by central imaging review(3 months from axi-cel infusion)
Modified EFS (mEFS) based on investigator assessment(at 12 months)
Duration of response (DOR)(at 3 years)
Overall survival (OS) from leukaphaeresis and Axi-cel infusion(at 3 years)

研究者

发起方

The Lymphoma Academic Research Organisation

申办方类型

Other

责任方

Sponsor

研究点 (16)

Loading locations...

相似试验

已完成

2 期

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaRefractory Large B-cell Lymphoma

NCT04002401Kite, A Gilead Company27

已完成

2 期

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaRelapsed or Refractory Large B-cell Lymphoma

NCT05459571Kite, A Gilead Company35

已完成

2 期

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaB-cell Lymphoma

NCT03761056Kite, A Gilead Company42

进行中（未招募）

3 期

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Follicular Lymphoma

NCT05371093Kite, A Gilead Company231

已完成

3 期

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03391466Kite, A Gilead Company359